An international team of researchers has developed a handheld, non-invasive device that can detect biomarkers for Alzheimer's and Parkinson's Diseases. The biosensor can also transmit the results wirelessly to a laptop or ...
Nov 13, 2023
0
30
Researchers at The University of Chicago have demonstrated that the type of bacteria living in the gut can influence the development of Alzheimer's disease symptoms in mice. The study, which will be published May 16 in the ...
May 16, 2019
0
16
In many neurodegenerative diseases like Parkinson's, protein aggregates form in the brain and are assumed to contribute to neuronal cell death. Yet there exists a cellular defense mechanism that counteracts these aggregates, ...
Nov 11, 2020
0
73
Beta-amyloid is a sticky protein that aggregates and forms small plaques in the brains of the elderly and is thought to be a cause of Alzheimer's disease. Because specialized immune cells always surround these plaques, many ...
Jan 29, 2015
0
32
Queensland scientists have found that non-invasive ultrasound technology can be used to treat Alzheimer's disease and restore memory.
Mar 12, 2015
0
170
Cycles of a diet that mimics fasting appear to reduce signs of Alzheimer's in mice genetically engineered to develop the illness, according to a new USC Leonard Davis School of Gerontology-led study.
Sep 27, 2022
0
96
Dutch scientists have discovered five biological variants of Alzheimer's disease, which may require different treatments. As a result, previously tested drugs may incorrectly appear to be ineffective or only minimally effective. ...
Jan 9, 2024
2
100
Highlighting a potential target in the treatment of multiple sclerosis (MS) and Alzheimer's disease, new research suggests that triggering a protein found on the surface of brain cells may help slow the progression of these ...
Mar 2, 2015
0
189
UPM researchers are involved in the development of a new biosensor that can be useful to achieve an early non-invasive diagnosis of Alzheimer's disease using magnetic resonance imaging.
Jul 12, 2018
0
5
Partner companies Eisai and Biogen recently announced promising clinical trial results for their new Alzheimer's drug lecanemab. Over 18 months, patients treated with lecanemab experienced slower symptom progression than ...
Oct 14, 2022
0
5
